MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase III drugs for Follicular Lymphoma have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how MIL-62’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MIL-62 is under development for the treatment of chronic lymphocytic leukemia, relapsed/refractory and previously untreated follicular lymphoma, relapsed/refractory and newly diagnosed diffuse large B cell lymphoma and intranodal marginal zone lymphoma, systemic lupus erythematosus (SLE), extranodal marginal zone lymphoma, splenic marginal zone lymphoma, lupus nephritis, primary membranous nephropathy, myasthenia gravis, neuromyelitis optica, relapsed/refractory B-cell non-Hodgkin lymphoma. The drug candidate is administered by intravenous drip route and acts by targeting cells expressing B-lymphocyte antigen CD20. It is a biobetter.
Beijing Mabworks Biotech overview
Beijing Mabworks Biotech (Beijing Mabworks Biotech Co) that develops and designs new prototype humanized and fully human monoclonal antibodies, oncology drugs, and other products. The company is headquartered in Beijing, Beijing, China.
For a complete picture of MIL-62’s drug-specific PTSR and LoA scores, buy the report here.